What induration size on a tuberculin skin test is considered positive, and what subsequent evaluation and treatment are recommended?

Positive TB Test Measurement

A tuberculin skin test (TST) is considered positive at three different induration thresholds—≥5 mm, ≥10 mm, or ≥15 mm—depending on the patient's risk category for tuberculosis infection and progression to active disease. 1, 2

Risk-Stratified Interpretation Thresholds

≥5 mm Induration (Highest Risk)

Consider the TST positive at ≥5 mm for patients in these categories 1, 2:

• HIV-infected persons
• Recent close contacts of infectious TB cases
• Patients with chest radiograph findings consistent with prior TB (fibrotic changes)
• Patients receiving immunosuppressive therapy (high-dose corticosteroids, TNF-α blocking agents)

≥10 mm Induration (Moderate Risk)

Consider the TST positive at ≥10 mm for 1, 2:

• Recent immigrants (within 5 years) from high TB prevalence countries
• Injection drug users
• Residents and employees of high-risk congregate settings (prisons, nursing homes, homeless shelters, hospitals)
• Healthcare workers with TB exposure
• Mycobacteriology laboratory personnel
• Patients with medical conditions increasing TB risk:
  • Silicosis
  • Diabetes mellitus
  • Chronic renal failure
  • Leukemias and lymphomas
  • Head/neck/lung carcinoma

  • 10% weight loss below ideal body weight

  • Gastrectomy or jejunoileal bypass
• Children <4 years old or adolescents exposed to high-risk adults

≥15 mm Induration (Low Risk)

Consider the TST positive at ≥15 mm only for persons with no known risk factors for TB 1. Testing this population is generally discouraged as targeted testing should focus on high-risk groups.

Important Caveats and Pitfalls

BCG vaccination history: Prior BCG vaccination can cause false-positive TST results, but an induration >14 mm is unlikely to be solely due to BCG 3. Current guidelines recommend treating all positive TSTs as true positives regardless of BCG history, though interferon-gamma release assays (IGRAs like QuantiFERON-TB Gold) can be used as an alternative or adjunct test in BCG-vaccinated individuals 3, 4.

False-negative reactions occur more frequently in 2:

• Infants and young children
• Early infection (<6-8 weeks after exposure)
• Severely immunocompromised patients (HIV, overwhelming TB disease)
• Recent viral vaccination or infection
• Patients on immunosuppressive medications

Boosting phenomenon: Repeated TST administration doesn't induce reactivity but can restore waned reactivity, which is why two-step testing is recommended for baseline screening in certain populations 2.

Subsequent Evaluation After Positive TST

1. Obtain chest radiograph to rule out active pulmonary TB
2. Assess for TB symptoms: cough, fever, night sweats, weight loss, hemoptysis
3. If chest X-ray is abnormal or symptoms present: Obtain sputum samples for AFB smear and culture to diagnose active TB disease
4. If chest X-ray is normal and asymptomatic: Diagnose as latent TB infection (LTBI)

Treatment Recommendations for LTBI

For confirmed LTBI (positive TST, normal chest X-ray, no symptoms), offer treatment regardless of age if the patient is at high risk for progression 1:

Preferred regimen: Isoniazid daily for 9 months (Rating A-II for both HIV-positive and HIV-negative) 1

Acceptable alternatives 1:

• Isoniazid daily for 6 months (Rating B-I for HIV-negative, C-I for HIV-positive)
• Rifampin-pyrazinamide for 2 months (Rating B-II for HIV-negative, A-I for HIV-positive)
• Rifampin daily for 4 months (Rating B-II for HIV-negative, B-III for HIV-positive)

The 9-month isoniazid regimen provides maximal benefit with minimal additional gain from extending to 12 months, while 6-month regimens offer substantial but somewhat reduced protection 1.